Filtered By:
Condition: Arthritis
Drug: Methotrexate

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 31 results found since Jan 2013.

Risk of Myocardial Infarction and Stroke in Patients with Granulomatosis with Polyangiitis: A Population‐Based Study
Conclusion: GPA patients have a significantly increased risk of MI, with a non‐statistically significant trend towards increased risk of ischemic stroke. Monitoring for this complication and vigilance in modifying risk factors is particularly warranted in this patient population, especially early after diagnosis. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - May 22, 2016 Category: Rheumatology Authors: J. Antonio Aviña‐Zubieta, Alice Mai, Neda Amiri, Natasha Dehghan, Ju Ann Tan, Eric C. Sayre, Hyon K. Choi Tags: Full Length Source Type: research

Risk of Myocardial Infarction and Stroke in Patients With Granulomatosis With Polyangiitis (Wegener's): A Population ‐Based Study
ConclusionPatients with GPA have a significantly increased risk of MI and a non–statistically significant trend toward an increased risk of ischemic stroke. Monitoring for this complication and vigilance in modifying risk factors are particularly warranted in this patient population, especially early after the diagnosis of GPA.
Source: Arthritis and Rheumatism - September 28, 2016 Category: Rheumatology Authors: J. Antonio Avi ña‐Zubieta, Alice Mai, Neda Amiri, Natasha Dehghan, Ju Ann Tan, Eric C. Sayre, Hyon K. Choi Tags: Full Length Source Type: research

Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population ‐based retrospective cohort study
ConclusionsAt a dosage of > 0.5 defined daily dose, short‐term methotrexate might decrease ischemic stroke risk in RA patients, while hydroxychloroquine and sulfasalazine were neutral.
Source: APLAR Journal of Rheumatology - January 1, 2018 Category: Rheumatology Authors: Hong ‐Wei Tam, Chyong‐Mei Chen, Pui‐Ying Leong, Chao‐Hsi Chen, Yuan‐Chao Li, Yu‐Hsun Wang, Li‐Chi Lin, Jeng‐Yuan Chiou, James Cheng‐Chung Wei Tags: Original Article Source Type: research

Prevention of Stroke in Rheumatoid Arthritis
Opinion statement Recognizing that systemic inflammation is a major contributor to the increased risk of cardiovascular disease (CVD), including stroke, in rheumatoid arthritis (RA) serves as the basis for prevention strategies for cerebrovascular disease in RA. In addition to traditional cardiovascular risk factors, recognize that RA may be an independent risk factor for cerebrovascular accident (CVA). The risk of CVD should be assessed in each patient with RA, utilizing modified risk score calculators. Careful monitoring and control of systemic inflammation should be undertaken in conjunction with assessing eac...
Source: Current Treatment Options in Neurology - May 18, 2015 Category: Neurology Source Type: research

Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review
Abstract Previous epidemiological studies have demonstrated a high prevalence of cardiovascular (CV) risk factors in psoriasis patients, including metabolic syndrome, cigarette smoking, obesity, hypertension, diabetes mellitus, insulin resistance and dyslipidaemia. An increase in CV morbidity and mortality attributable to psoriasis is still under question. Primary objective: to assess CV morbidity and mortality in psoriasis and psoriatic arthritis (PsA) including stroke, coronary artery disease, myocardial infarction (MI) and peripheral artery disease. Secondary objectives: to assess if psoriasis per se is an independent C...
Source: Journal of the European Academy of Dermatology and Venereology - July 11, 2013 Category: Dermatology Authors: C. Horreau, C. Pouplard, E. Brenaut, T. Barnetche, L. Misery, B. Cribier, D. Jullien, S. Aractingi, F. Aubin, P. Joly, M. Maître, J.‐P. Ortonne, C. Paul, M.‐A. Richard Tags: Review Article Source Type: research

A Case Report of Rheumatoid Meningitis, an unusual complication of Rheumatoid Arthritis (P4.056)
CONCLUSIONS: Rheumatoid Meningitis is an extremely uncommon complication of Rheumatoid Arthritis. Initial presentations can vary from altered mental status (most common), cranial neuropathies, hemiparesis/paraparesis, seizure, headache and very rarely stroke like symptoms. This patient with Rheumatoid Arthritis presented with multiple stroke like episodes, lepomeningeal enhancement. Diagnosis was established on the basis of Imaging and Histopathology after excluding other potential causes of granulomatous meningitis. Study Supported by: Not applicableDisclosure: Dr. roy has nothing to disclose. Dr. Brink has nothing to dis...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Roy, B., Brink, J., Bakradze, E., Al Zahmi, F., Uphoff, D., Silverman, I. Tags: MS and CNS Inflammatory Diseases: CNS Inflammatory Diseases and Differential Diagnosis Source Type: research

Benefits of Methotrexate Use on Cardiovascular Disease Risk among Rheumatoid Arthritis Patients Initiating Biologic Disease-Modifying Antirheumatic Drugs.
CONCLUSION: Among RA patients receiving biologics, concomitant methotrexate use was associated with a 24% lower risk for CVD events. PMID: 33060309 [PubMed - as supplied by publisher]
Source: J Rheumatol - October 15, 2020 Category: Rheumatology Authors: Xie F, Chen L, Yun H, Levitan EB, Curtis JR Tags: J Rheumatol Source Type: research

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
Background: Inflammation plays a fundamental role in atherothrombosis. Yet, whether direct inhibition of inflammation will reduce the occurrence of adverse cardiovascular outcomes is not known.Design: The Cardiovascular Inflammation Reduction Trial (CIRT) (ClinicalTrials.gov NCT01594333) will randomly allocate 7,000 patients with prior myocardial infarction (MI) and either type 2 diabetes or the metabolic syndrome to low-dose methotrexate (target dose 15-20 mg/wk) or placebo over an average follow-up period of 3 to 5 years. Low-dose methotrexate is a commonly used anti-inflammatory regimen for the treatment of rheumatoid a...
Source: American Heart Journal - May 6, 2013 Category: Cardiology Authors: Brendan M. Everett, Aruna D. Pradhan, Daniel H. Solomon, Nina Paynter, Jean MacFadyen, Elaine Zaharris, Milan Gupta, Michael Clearfield, Peter Libby, Ahmed A.K. Hasan, Robert J. Glynn, Paul M. Ridker Tags: Trial Design Source Type: research

Hacking The Nervous System
(Photo: © Job Boot) One nerve connects your vital organs, sensing and shaping your health. If we learn to control it, the future of medicine will be electric.When Maria Vrind, a former gymnast from Volendam in the Netherlands, found that the only way she could put her socks on in the morning was to lie on her back with her feet in the air, she had to accept that things had reached a crisis point. “I had become so stiff I couldn’t stand up,” she says. “It was a great shock because I’m such an active person.”It was 1993. Vrind was in her late 40s and working two jobs, athletics coach and a carer for disabled ...
Source: Science - The Huffington Post - May 30, 2015 Category: Science Source Type: news

Patients with rheumatoid arthritis have impaired long-term outcomes after myocardial infarction: a nationwide case-control registry study
ConclusionRA is independently associated with poorer prognosis after MI. RA duration and corticosteroid usage and dosage were independent predictors of mortality after MI in RA. Special attention is needed for improvement of outcomes after MI in this vulnerable population.
Source: Rheumatology - March 1, 2021 Category: Rheumatology Source Type: research

Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-α Blockade with Nonbiologic DMARDs
Conclusion: Among subjects with rheumatoid arthritis, TNF-α blocking agents may be associated with a reduced risk of cardiovascular events compared with an nbDMARD. Randomized controlled clinical trials should be considered to test this hypothesis.
Source: The American Journal of Medicine - July 26, 2013 Category: Journals (General) Authors: Daniel H. Solomon, Jeffrey R. Curtis, Kenneth G. Saag, Joyce Lii, Lang Chen, Leslie R. Harrold, Lisa J. Herrinton, David J. Graham, Mary K. Kowal, Bindee Kuriya, Liyan Liu, Marie R. Griffin, James D. Lewis, Jeremy A. Rassen Tags: Clinical research studies Source Type: research

TNF‐α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis patients
Conclusion: Use of TNF‐α inhibitors is associated with a decreased risk for CAD in RA; the risk decreases further with longterm use. This should be considered when weighing the risks versus benefits of these medications. © 2013 American College of Rheumatology.
Source: Arthritis Care and Research - September 10, 2013 Category: Rheumatology Authors: Androniki Bili, Xiaoqin Tang, Shruthi Pranesh, Rasa Bozaite, Stephanie J. Morris DO, Jana L. Antohe, H. Lester Kirchner, Mary Chester M. Wasko Tags: Original Article Source Type: research

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
Conclusions Among RA patients, there is a high prevalence of comorbidities and their risk factors. In this multinational sample, variability among countries was wide, not only in prevalence but also in compliance with recommendations for preventing and managing these comorbidities. Systematic measurement of vital signs and laboratory testing detects otherwise unrecognised comorbid conditions.
Source: Annals of the Rheumatic Diseases - December 4, 2013 Category: Rheumatology Authors: Dougados, M., Soubrier, M., Antunez, A., Balint, P., Balsa, A., Buch, M. H., Casado, G., Detert, J., El-zorkany, B., Emery, P., Hajjaj-Hassouni, N., Harigai, M., Luo, S.-F., Kurucz, R., Maciel, G., Mola, E. M., Montecucco, C. M., McInnes, I., Radner, H., Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Osteoporosis, Rheumatoid arthritis, Epidemiology, Calcium and bone Clinical and epidemiological research Source Type: research

Tumor Necrosis Factor α Inhibitor Use and Decreased Risk for Incident Coronary Events in Rheumatoid Arthritis
ConclusionUse of TNFα inhibitors is associated with a decreased risk for CAD in RA; the risk decreases further with long‐term use. This should be considered when weighing the risks versus benefits of these medications.
Source: Arthritis Care and Research - February 24, 2014 Category: Rheumatology Authors: Androniki Bili, Xiaoqin Tang, Shruthi Pranesh, Rasa Bozaite, Stephanie J. Morris, Jana L. Antohe, H. Lester Kirchner, Mary Chester M. Wasko Tags: Rheumatoid Arthritis Source Type: research